FDA Drug Recalls

Recalls / Class II

Class IID-0435-2023

Product

Heparin Sodium Injection, USP, 20,000 USP units per mL, 25 x 1 mL Multi-Dose Vials, Rx Only, For Intravenous or Subcutaneous Use, Mfd. for: Sagent Pharmaceuticals, Schaumburg, IL 60195; Made in India, NDC carton: 25021-404-01

Brand name
Heparin Sodium
Generic name
Heparin Sodium
Active ingredient
Heparin Sodium
Route
Intravenous, Subcutaneous
NDC
25021-404
FDA application
ANDA090809
Affected lot / code info
Lot#: WP201, Exp 2/2024

Why it was recalled

Labeling: Not elsewhere classified

Recalling firm

Firm
Sagent Pharmaceuticals Inc
Manufacturer
Sagent Pharmaceuticals
Notification channel
Letter
Type
Voluntary: Firm initiated
Address
1901 N Roselle Rd Ste 450, Schaumburg, Illinois 60195-3194

Distribution

Quantity
28,875 vials
Distribution pattern
USA Nationwide

Timeline

Recall initiated
2023-02-28
FDA classified
2023-03-06
Posted by FDA
2023-03-15
Status
Completed

Source: openFDA Drug Enforcement endpoint. Recall record D-0435-2023. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.

Class II recall: Heparin Sodium · FDA Drug Recalls